All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

Dow Jones01-17

1703 GMT - Big European pharmaceutical stocks have rallied in recent weeks, which makes them vulnerable should companies' 2026 guidance disappoint, Bank of America analysts say in a note. The likely outlooks from AstraZeneca and Novartis look safe relative to consensus expectations, Bank of America says. Meanwhile, there could be some risk that the outlooks issued by GSK, Novo Nordisk and Sanofi fall short of forecasts, according to Bank of America. For Roche, Bank of America expects guidance of sales growth in the mid-single-digit percentage range excluding currency movements and earnings per share growth of high single digits, broadly in line with consensus, but sees room for a more cautious view. The Stoxx Europe 600 Health Care index closes 0.6% higher, and is up 7.25% over the past month. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 12:03 ET (17:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment